Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 3
2009 1
2010 1
2011 2
2012 2
2013 1
2014 4
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Management of gender dysphoria in adolescents in primary care.
Bonifacio JH, Maser C, Stadelman K, Palmert M. Bonifacio JH, et al. Among authors: stadelman k. CMAJ. 2019 Jan 21;191(3):E69-E75. doi: 10.1503/cmaj.180672. CMAJ. 2019. PMID: 30665976 Free PMC article. Review. No abstract available.
Akt as a therapeutic target in cancer.
Steelman LS, Stadelman KM, Chappell WH, Horn S, Bäsecke J, Cervello M, Nicoletti F, Libra M, Stivala F, Martelli AM, McCubrey JA. Steelman LS, et al. Among authors: stadelman km. Expert Opin Ther Targets. 2008 Sep;12(9):1139-65. doi: 10.1517/14728222.12.9.1139. Expert Opin Ther Targets. 2008. PMID: 18694380 Review.
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.
Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA. Davis NM, et al. Among authors: stadelman k. Oncotarget. 2014 Jul 15;5(13):4603-50. doi: 10.18632/oncotarget.2209. Oncotarget. 2014. PMID: 25051360 Free PMC article. Review.
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.
Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Steelman LS, McCubrey JA. Chappell WH, et al. Among authors: stadelman km. Adv Biol Regul. 2013 Jan;53(1):146-55. doi: 10.1016/j.jbior.2012.09.004. Epub 2012 Sep 16. Adv Biol Regul. 2013. PMID: 23073564 No abstract available.
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies.
Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, Miller LD, Stadelman KM, Levitan D, Hurd D, Ellis LR, Harrelson R, Manuel M, Dralle S, Lyerly S, Powell BL. Pardee TS, et al. Among authors: stadelman km. Clin Cancer Res. 2014 Oct 15;20(20):5255-64. doi: 10.1158/1078-0432.CCR-14-1019. Epub 2014 Aug 27. Clin Cancer Res. 2014. PMID: 25165100 Free PMC article. Clinical Trial.
Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors.
Steelman LS, Navolanic PM, Sokolosky ML, Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Wong EW, Stadelman KM, Terrian DM, Leslie NR, Martelli AM, Stivala F, Libra M, Franklin RA, McCubrey JA. Steelman LS, et al. Among authors: stadelman km. Oncogene. 2008 Jul 3;27(29):4086-95. doi: 10.1038/onc.2008.49. Epub 2008 Mar 10. Oncogene. 2008. PMID: 18332865 Free PMC article.
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.
Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA. Sokolosky ML, et al. Among authors: stadelman km. Oncotarget. 2011 Jul;2(7):538-50. doi: 10.18632/oncotarget.302. Oncotarget. 2011. PMID: 21730367 Free PMC article.
13 results